Company news
Alaunos Therapeutics, Inc. news in 2026
Alaunos Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
October 13, 2026
Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
October 13, 2026
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
September 18, 2026
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study
June 29, 2026
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
May 26, 2026
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
May 18, 2026
Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
March 2, 2026
Decks in 2026
- Merger or Acquisition (October 2026)
Merger or acquisition · 26 slides · Oct 13, 2026
- Technical Presentation (May 2026)
Technical · 23 slides · May 26, 2026